Date | 22 March 2021 | – present
---|---|
Location | Taiwan |
Cause | COVID-19 pandemic in Taiwan |
Target | Immunization against COVID-19 |
Budget | 18.7 billion NT$[1] |
Organized by | Taiwan Centers for Disease Control |
Participants | 21,802,750 people have received at least one vaccine dose 20,546,190 people have been fully vaccinated 17,220,124 people have received a booster dose 4,018,016 people have received two booster doses 386,543 people have received three booster doses as of 21 October 2022[2] |
Outcome | 94% of the Taiwanese population have received at least one vaccine dose 88.6% of the Taiwanese population have been fully vaccinated 74% of the Taiwanese population have received a booster dose 17.3% of the Taiwanese population have received two booster doses 1.7% of the Taiwanese population have received three booster doses as of 27 November 2022 |
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country.
As of February 23, 2023, Taiwan's Central Epidemic Command Center (CECC) said that 94% of the population had received at least one dose of COVID-19 vaccine, 76.3% had had a booster shot, and 23% had received a third dose.[3]
As of 21 October 2022, 21,761,873 people, or 93.81% of the Taiwanese population has received at least one dose, while 20,447,829 people, or 88.14% of the population have received at least two doses, while 17,102,993, or 73.73% of the population have received at least three, while 3,300,926 people, or 14.23% of the population having received at least four, and 249,559 people, or 1.1% of the population, having received all five. A further 185,463 immunocompromised individuals, or 0.8% of the population, have received a weakened version of the booster dose. 93.96% of those over 12 have received the first booster dose, while 41.4% of those over 65 have received the second booster dose.[4]
Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 18 March 2021, vaccinations commenced on 22 March 2021, and will continue throughout the year with the goal of vaccinating 70% of the population by late October 2021.[5]